Breaking Frontiers-Leadless Atrial-Ventricular Hybrid Upgrade to Dual Chamber Leadless Pacemaker.

Pacing Clin ElectrophysiolApr 13, 2026 (epub)
Case ReportCardiology

João Mendes Cravo, Diogo Rosa Ferreira, Ana Abreu Bernardes et al.

✦ AI-curated · Sources linked

Case in brief

An 87-year-old man with stage 5 chronic kidney disease receiving haemodialysis had complete atrioventricular block managed with a Micra-AV leadless pacemaker. He later developed symptomatic sinus node dysfunction. To provide atrial pacing and restore atrioventricular synchrony while avoiding transvenous implantation, clinicians added an Abbott AVEIR AR atrial leadless pacemaker, creating a functional dual-chamber system using devices from different manufacturers. The procedure was uncomplicated. Follow-up showed 89% atrioventricular synchrony and symptomatic improvement.

What made this case unusual

The hybrid system paired leadless pacemakers from two different manufacturers to provide functional dual-chamber pacing.

Diagnostic / clinical pearl

When symptomatic sinus node dysfunction develops in a patient with an existing leadless ventricular pacemaker, an atrial leadless device may enable functional dual-chamber pacing while avoiding transvenous implantation in selected patients.

Source

PubMed · PMID 41972784

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.